JamesTateThigpenMD

Oncology • Jackson, MS

Professor, Medicine, University of Mississippi School of Medicine

Join to view full profile

Dr. Thigpen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Thigpen's full profile

Already have an account?

Office
2500 North State Street
Department Of Medicine/Division Of Oncology
Jackson, MS 39216
Phone+1 601-366-9341
Is this information wrong?

Education & Training

University of Mississippi Medical CenterResidency, Internal Medicine, 1970 - 1973
University of Mississippi Medical CenterFellowship, Hematology and Medical Oncology, 1968 - 1971
University of RochesterInternship, Internal Medicine, 1969 - 1970
University of Mississippi School of MedicineClass of 1969

Certifications & Licensure

MS State Medical License 1969 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Paclitaxel in Treating Patients With Ovarian Stromal Cancer Start of enrollment: 2000 Nov 20
Completed
Phase 2
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
Active, not recruiting
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2008 Sep 01
Completed
Phase 2
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
Collecting Tumor Samples From Patients With Gynecological Tumors Start of enrollment: 1992 Jun 01
Completed
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01
Terminated
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 2
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
Active, not recruiting
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Nov 01
Completed
Phase 2
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2010 Jun 01
Completed
Phase 2
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Start of enrollment: 2010 Aug 01
Completed
Phase 2
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 06
Completed
Phase 2
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2011 Oct 01
Completed
Phase 2
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Start of enrollment: 2011 Apr 04
Completed
Phase 2
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14
Completed
Phase 1
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Mar 21
Completed
Phase 2
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer Start of enrollment: 2012 Feb 22
Active, not recruiting
Phase 2
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Francis S. Morrison MD-Tribute to an apheresis leader.
Walter Linz, James T Thigpen, Ronald G Strauss> ;Journal of Clinical Apheresis. 2023 Oct 1
342 citations
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncolog...
Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas J. Reid, Mario M. Leitao, Helen Michael,...> ;Lancet. 2017 Oct 7
19 citations
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/G...
Phuong L. Mai, Marion Piedmonte, Paul Kyu Han, Richard P. Moser, Joan L. Walker, Gustavo C. Rodriguez, John F. Boggess, Thomas J. Rutherford, Oliver Zivanovic, David E...> ;Gynecologic Oncology. 2017 Apr 1
30 citations
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group an...
Kathleen N. Moore, James J. Java, Katrina N. Slaughter, Peter G. Rose, Rachelle Lanciano, Paul DiSilvestro, J. Tate Thigpen, Yi-Chun Lee, Krishnansu S. Tewari, Junzo C...> ;Gynecologic Oncology. 2016 Nov 1
9 citations
Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and over...
J. Tate Thigpen> ;Gynecologic Oncology. 2015 Jan 1
6 citations
Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study
Frederick B. Stehman, Mark F. Brady, J. Tate Thigpen, Emma C. Rossi, Robert A. Burger> ;Gynecologic Oncology. 2012 Dec 1
17 citations
Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiati...
Krishnansu S. Tewari, Virginia L. Filiaci, Nick M. Spirtos, Robert S. Mannel, J. Tate Thigpen, Michael L. Cibull, Bradley J. Monk, Marcus E. Randall> ;Gynecologic Oncology. 2012 Apr 1
23 citations
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? A gynecologic o...
Kathleen N. Moore, Chunqiao Tian, D. Scott McMeekin, J. Tate Thigpen, Marcus E. Randall, Holly H. Gallion> ;Cancer. 2010 Dec 1
185 citations
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
Gini F. Fleming, Michael W. Sill, Kathleen M. Darcy, D. Scott McMeekin, J. Tate Thigpen, Lisa M. Adler, Jonathan S. Berek, Julia Chapman, P. DiSilvestro, Ira R. Horowi...> ;Gynecologic Oncology. 2010 Jan 1
52 citations
Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop
Robert C. Bast, J. Tate Thigpen, Susan G. Arbuck, Karen Basen-Engquist, Laurie B. Burke, Ralph S. Freedman, Sandra J. Horning, Robert F. Ozols, Gordon J. S. Rustin, Da...> ;Gynecologic Oncology. 2007 Nov 1
19 citations
Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Lenora Bigler, J. Tate Thigpen, John A. Blessing, James V. Fiorica, Bradley J. Monk> ;International Journal of Gynecological Cancer. 2004 Sep 1
9 citations
Management of women who present with T4 breast cancer.
Galen V. Poole, J. Tate Thigpen, Ralph B. Vance, W. Henry Barber, Laura E. Witherspoon, George M. Fuhrman, T. Chadwick Eustis, David V. Feliciano> ;The American Surgeon. 2004 Aug 1
52 citations
Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study.
J. Tate Thigpen, John A. Blessing, Koen DeGeest, Katherine Y. Look, Howard D. Homesley> ;Gynecologic Oncology. 2004 May 1
15 citations
Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men
Charles F. Streckfus, Lenora Bigler, T M Dellinger, Xaoli Dai, W. Jason Cox, Ashley McArthur, Albert Kingman, J. Tate Thigpen> ;Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 2001 Feb 1
50 citations
Chemotherapy for advanced ovarian cancer: overview of randomized trials.
James Tate Thigpen> ;Seminars in Oncology. 2000 Jun 1
101 citations
A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma.
Charles F. Streckfus, Lenora Bigler, Michelle Tucci, James Tate Thigpen> ;Cancer Investigation. 2000 Jan 1
20 citations
Chemotherapy for ovarian cancer: current concepts.
V. E. Herrin, J. Tate Thigpen> ;Seminars in Surgical Oncology. 1999 Oct 1
21 citations
CA 15-3 and c-erbB-2 presence in the saliva of women.
Charles F. Streckfus, Lenora Bigler, T M Dellinger, M. Pfeifer, A. Rose, James Tate Thigpen> ;Clinical Oral Investigations. 1999 Sep 1
11 citations
Basal cell carcinoma with lung metastasis diagnosed by fine-needle aspiration biopsy.
Manubhai S. Patel, James Tate Thigpen, Ralph B. Vance, S. Elkins, Ming Guo> ;Southern Medical Journal. 1999 Mar 1
34 citations
Salivary slgA concentrations and stimulated whole saliva flow rates among women undergoing chemotherapy for breast cancer: an exploratory study
Tonya Harrison, Lenora Bigler, Michelle Tucci, Lillian Pratt, Fernando Malamud, James Tate Thigpen, Charles F. Streckfus, Hope Younger> ;Special Care in Dentistry. 1998 May 1
31 citations
Chemotherapy as a palliative treatment in carcinoma of the uterine cervix.
James Tate Thigpen, Ralph B. Vance, Louis V. Puneky, Tawfiq Khansur> ;Seminars in Oncology. 1995 Apr 1
119 citations
A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic O...
Thigpen Jt, John A. Blessing, Philip J. DiSaia, Edgardo Yordan, L F Carson, C Evers> ;Journal of Clinical Oncology. 1994 Jul 1
22 citations
Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
Geoffrey R. Weiss, Stephanie Green, James Tate Thigpen, Harry E. Hines, Karl Hanson, H. Irving Pierce, Laurence H. Baker, John Wendall Goodwin, David S. Alberts> ;European Journal of Cancer. 1991 Jan 1
10 citations
Preoperative evaluation with radionuclide brain scanning and computerized axial tomography of the brain in patients with breast cancer.
Tawfiq Khansur, Alexander J. Haick, Bharati Patel, Lodovico Balducci, Ralph B. Vance, James Tate Thigpen> ;American Journal of Surgery. 1988 Feb 1
26 citations
Nutrition, cancer, and aging: an annotated review. II. Cancer cachexia and aging.
Cheryl L. Hardy, C. Wallace, Tawfiq Khansur, Ralph B. Vance, James Tate Thigpen, Lodovico Balducci> ;Journal of the American Geriatrics Society. 1986 Mar 1
Join now to see all

Press Mentions

New Concepts Emerging in Treatment of Advanced Ovarian CancerDecember 16th, 2015
Intraperitoneal Chemotherapy Uptake Sluggish in Ovarian CancerAugust 11th, 2015

Hospital Affiliations

University of Mississippi Medical CenterJackson, Mississippi

JamesTateThigpenMD

Dr. Thigpen is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.